NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism.

The article reports on the results of the pivotal Phase 3 REPLACE study of NPSP558 in hypoparathyroidism by NPS Pharmaceuticals Inc. It notes that NPSP558 is the company's bioengineered replica of human parathyroid hormone for the treatment of hypoparathyroidism. It adds that the REPLACE study has shown positive results, which expect to file for Food and Drug Administration (FDA) approval of the drug in 2012.